Celestia S Higano Selected Research

Mitoxantrone (Novantrone)

1/2017	Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database.
1/2017	Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.
9/2015	A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
1/2014	Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.
8/2012	New treatment options for patients with metastatic castration-resistant prostate cancer.
4/2010	Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.
4/2010	Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
10/2007	Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15.
5/2006	Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer.
2/2004	Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Celestia S Higano Research Topics

Disease

168	Prostatic Neoplasms (Prostate Cancer) 09/2022 - 01/2003
53	Neoplasms (Cancer) 06/2022 - 05/2003
42	Neoplasm Metastasis (Metastasis) 06/2022 - 01/2003
8	Pain (Aches) 06/2022 - 05/2013
7	Fatigue 01/2022 - 04/2010
7	Circulating Neoplastic Cells 01/2022 - 04/2014
7	Disease Progression 01/2021 - 07/2006
6	Carcinoma (Carcinomatosis) 01/2014 - 03/2003
4	Cardiovascular Diseases (Cardiovascular Disease) 10/2021 - 01/2020
4	Osteoporosis 01/2013 - 12/2003
3	Hypertension (High Blood Pressure) 12/2020 - 07/2014
3	Lymphatic Metastasis 04/2010 - 05/2005
2	Breast Neoplasms (Breast Cancer) 06/2022 - 05/2003
2	Nausea 01/2022 - 05/2013
2	Adenocarcinoma 01/2021 - 10/2013
2	Febrile Neutropenia 01/2019 - 01/2017
2	Neutropenia 01/2017 - 05/2006
2	Cancer Pain 01/2017 - 01/2013
2	Bone Diseases (Bone Disease) 10/2016 - 04/2010
2	Diarrhea 10/2014 - 05/2013
2	Hot Flashes 09/2012 - 02/2003
2	Margins of Excision 01/2009 - 05/2006
2	Erectile Dysfunction 12/2008 - 08/2007
2	Cachexia 05/2003 - 03/2003
1	Genetic Risk Score 01/2022
1	Dizziness (Lightheadedness) 01/2022

Drug/Important Bio-Agent (IBA)

56	AndrogensIBA 01/2021 - 02/2003
32	Prostate-Specific Antigen (Semenogelase)IBA 01/2022 - 02/2003
30	Docetaxel (Taxotere)FDA Link 12/2021 - 02/2004
23	enzalutamideIBA 09/2022 - 05/2009
20	Hormones (Hormone)IBA 02/2018 - 09/2003
17	Androgen Receptors (Androgen Receptor)IBA 12/2020 - 06/2008
17	sipuleucel-T (APC8015)FDA Link 01/2020 - 07/2006
11	Abiraterone AcetateIBA 01/2022 - 09/2012
11	Prednisone (Sone)FDA LinkGeneric 01/2021 - 01/2013
10	Biomarkers (Surrogate Marker)IBA 02/2018 - 05/2009
10	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2017 - 02/2004
8	Radium-223IBA 01/2022 - 08/2012
8	Gonadotropin-Releasing Hormone (GnRH)FDA Link 10/2021 - 05/2005
8	Proteins (Proteins, Gene)FDA Link 10/2016 - 05/2003
8	Diphosphonates (Bisphosphonates)IBA 08/2013 - 01/2003
7	abirateroneIBA 12/2021 - 08/2012
7	Pharmaceutical PreparationsIBA 01/2021 - 11/2015
7	Zoledronic Acid (Zometa)FDA Link 11/2011 - 01/2003
6	Testosterone (Sustanon)FDA Link 01/2021 - 06/2008
5	Leuprolide (Lupron)FDA LinkGeneric 10/2021 - 06/2010
4	bicalutamide (Casodex)FDA LinkGeneric 09/2022 - 05/2015
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2021 - 01/2020
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 03/2009
4	cabazitaxel FDA Link 01/2017 - 08/2012
4	EnzymesIBA 10/2016 - 06/2008
3	taxaneIBA 06/2022 - 12/2007
3	rucaparibIBA 12/2021 - 01/2020
3	Hemoglobins (Hemoglobin)IBA 10/2019 - 06/2007
3	Alkaline PhosphataseIBA 10/2019 - 09/2008
3	RadiumIBA 01/2019 - 01/2013
3	Androgen Antagonists (Antiandrogens)IBA 11/2018 - 05/2009
3	cixutumumabIBA 02/2018 - 05/2015
3	AtrasentanIBA 01/2017 - 08/2013
3	RadiopharmaceuticalsIBA 12/2013 - 11/2007
3	Endothelins (Endothelin)IBA 08/2013 - 07/2012
2	talazoparibIBA 06/2022 - 01/2021
2	Denosumab FDA Link 06/2022 - 11/2011
2	acetyl- 2- naphthylalanyl- 3- chlorophenylalanyl- 1- oxohexadecyl- seryl- 4- aminophenylalanyl(hydroorotyl)- 4- aminophenylalanyl(carbamoyl)- leucyl- ILys- prolyl- alaninamide FDA Link 10/2021 - 03/2020
2	AntigensIBA 12/2019 - 08/2015
2	MicroRNAs (MicroRNA)IBA 02/2018 - 10/2014
2	OGX-011IBA 01/2017 - 01/2013
2	Androgen Receptor AntagonistsIBA 12/2016 - 04/2013
2	LigandsIBA 11/2016 - 10/2013
2	Biological ProductsIBA 03/2016 - 02/2004
2	Chromogranin AIBA 10/2015 - 07/2003
2	prostatic acid phosphataseIBA 08/2015 - 06/2011
2	cabozantinibIBA 02/2015 - 10/2014
2	Flutamide (Eulexin)FDA LinkGeneric 02/2015 - 06/2010
2	Narcotics (Narcotic Analgesics)IBA 02/2015 - 10/2014
2	ZD4054IBA 05/2013 - 07/2012
2	Endothelin A ReceptorIBA 05/2013 - 07/2012
2	LipidsIBA 01/2013 - 02/2003
2	Messenger RNA (mRNA)IBA 01/2013 - 05/2003
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 04/2012 - 09/2008
2	CytokinesIBA 10/2007 - 03/2003
2	Estrogens (Estrogen)FDA Link 10/2004 - 02/2003
1	Complement System Proteins (Complement)IBA 06/2022
1	Monoclonal AntibodiesIBA 06/2022
1	AZD8186IBA 01/2022
1	TEMPOIBA 01/2022
1	SiliconIBA 01/2022
1	Epithelial Cell Adhesion MoleculeIBA 01/2022
1	vistusertibIBA 01/2022

Therapy/Procedure

97	Castration 09/2022 - 11/2007
82	Therapeutics 01/2022 - 02/2003
41	Drug Therapy (Chemotherapy) 06/2022 - 06/2005
15	Immunotherapy 12/2019 - 02/2004
15	Prostatectomy (Retropubic Prostatectomy) 01/2017 - 02/2004
7	Radiotherapy 09/2012 - 06/2005
6	Neoadjuvant Therapy 01/2014 - 05/2006
4	Aftercare (After-Treatment) 01/2022 - 03/2015
2	Brachytherapy 09/2012 - 12/2008
1	Duration of Therapy 06/2022
1	Ambulatory Care (Outpatient Care) 06/2022